Giant cell arteritis

Curr Opin Ophthalmol. 2007 Nov;18(6):443-9. doi: 10.1097/ICU.0b013e3282f0b4a9.

Abstract

Purpose of review: Giant cell arteritis is an important cause of blindness in patients over 60 years of age. We attempt to identify the important clinical aspects in the diagnosis and management of this disorder, so that treatment may be instituted expeditiously to limit visual loss.

Recent findings: In addition, we identify current areas of standards in the investigation and treatment of patients with suspected giant cell arteritis.

Summary: We review some newer treatment possibilities, based on recently proposed immunologic models of giant cell arteritis, that may lead to newer treatment modalities.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / therapeutic use
  • Biopsy
  • Drug Administration Schedule
  • Giant Cell Arteritis / complications
  • Giant Cell Arteritis / diagnosis*
  • Giant Cell Arteritis / drug therapy*
  • Giant Cell Arteritis / etiology
  • Humans
  • Methotrexate / therapeutic use
  • Methylprednisolone / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis
  • Vision Disorders / etiology

Substances

  • Adrenal Cortex Hormones
  • Platelet Aggregation Inhibitors
  • Methylprednisolone
  • Methotrexate